UK premarket pathways for medical devices: CE transition, UKCA and obligations

1. Key takeaways

Great Britain currently offers exactly two practically available premarket routes for medical devices. The first is the transitional arrangement built on CE certificates (regulations 19B, 19C, 30A, 44ZA and 44ZB). The second is domestic UKCA conformity assessment, using the placing-on-the-market procedures in Part II, Part III and Part IV of the UK Medical Devices Regulations 2002. A third route, an international reliance pathway, remains at proposal stage: the relevant statutory instrument has not yet been made or brought into force, so no company can rely on it today.

Companies should first determine which of these routes their products fall under, and only then work backwards to the standing obligations that travel with the product into the market: appointment of a UK responsible person (UKRP), registration with the MHRA, and post-market surveillance (PMS). These three obligations are entirely independent of the route choice and apply in every case. A product entering on a CE certificate and a product entering on a UKCA certificate carry identical UKRP, MHRA registration and PMS duties, on the same timescales and with the same enforcement exposure. Treating the transition as a compliance holiday is therefore one of the most common and most expensive planning errors seen in Great Britain market entry projects.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 19B (discharging Part II obligations by relying on Directive 93/42), reg 19C (discharging Part II and Part III obligations by relying on EU 2017/745), reg 30A (discharging Part III obligations by relying on Directive 90/385), reg 44ZA (discharging Part IV obligations by relying on Directive 98/79), reg 44ZB (discharging Part IV obligations by relying on EU 2017/746); reg 1ZA (the expiry points of those provisions); regs 13, 27 and 40 (the UKCA marking procedures).
• SI 2023/627 (made on 9 June 2023): reg 4 replaces reg 1ZA and fixes the two expiry points of 2028 and 2030.
• Government response: the document titled ‘Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices’ (consultation ran from 16 February 2026 to 10 April 2026; the response was published on 21 October 2026).

3. Expert insights

Insight one: the five duty-discharge provisions are five transition corridors. The legislative technique behind reg 19B, 19C, 30A, 44ZA and 44ZB is straightforward: if you already comply with a named piece of EU law, you are treated as having discharged the corresponding duty under the UK regime. Together these five provisions form the statutory interface through which CE marked devices enter Great Britain. Which one applies to a given product depends on two variables only: the product part (general devices, active implantable devices, or IVDs) plus the EU law the certificate rests on. Mapping those two variables correctly is the entire first step of any route analysis, and getting the part wrong sends the whole downstream plan to the wrong regulation.

Insight two: routes and obligations form a two-layer structure. The route decides by what right a product enters; the obligations decide what must be done once it is in. The British structure is distinctive because long-term recognition of CE marking only changes the first layer. The second layer, comprising the UKRP, MHRA registration and PMS, remains untouched regardless of how long CE certificates keep working. This is precisely where many companies misjudge the market: they assume that recognition of CE marking means the United Kingdom no longer demands anything of them. In reality the national obligations sit outside the CE framework altogether and continue to bite.

Insight three: progress on the third route must be separated into policy and legislation. In the official consultation response, the proposal to create a separate international reliance route for devices whose UK classification sits higher than their EU classification did not attract majority support. In parallel, a broader reliance concept, under which approvals from Australia, Canada and the United States would be recognised, has been folded into the proposed premarket statutory instrument. However, as of the date of checking, there is no enacted statutory text in force. Until an instrument is made and commences, the reliance route exists on paper only, and planning production or launch dates around it carries real commercial risk.

A fourth observation concerns timing discipline. Because the two fixed expiry points and the certificate dates interact, the effective runway of each product is a computed value rather than a published one, and it changes every time a certificate is renewed, withdrawn or allowed to lapse. Companies that treat the runway as a one-off assessment made at project kick-off routinely discover, late and at cost, that a certificate renewal in one jurisdiction silently moved their British market position. Building the matrix so that certificate data flows into it automatically, rather than being re-typed by hand, is the single most effective safeguard against that failure mode.

4. Practical recommendations

GRZAN recommends managing every Great Britain project through a single route-versus-obligation matrix. The horizontal axis lists the five routes: CE-MDD, CE-MDR, CE-IVDD, CE-IVDR and UKCA. The vertical axis lists the six obligations: classification, conformity assessment, marking, UKRP, MHRA registration and PMS. Each cell is then annotated with the applicable regulation and its status point in time. The matrix turns scattered regulatory reading into a controlled document, makes gaps visible at a glance, and gives auditors and management a single artefact to review. It should be re-verified quarterly as the rules move.

In operating the matrix, GRZAN further recommends separating two decision horizons. The first horizon is the entry decision: which corridor the product uses to reach the market now, based on the certificates it actually holds. The second horizon is the renewal decision: whether to maintain that corridor, migrate to another one, or hold a dual position. Keeping the two horizons in separate columns prevents the common confusion in which a long-term policy announcement is treated as though it had already changed today’s entry rights, which it has not.

5. Verification checklist

• □ The applicable transition provision has been determined (19B / 19C / 30A / 44ZA / 44ZB)
• □ Certificate status and expiry dates have been confirmed
• □ The three standing obligations, UKRP, MHRA registration and PMS, have all been arranged
• □ Policy confirmations and enacted legislation have been distinguished as separate information sources
• □ The route-versus-obligation matrix has been built and a review owner has been named

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.